NEOS
A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension. Additional PIP decision number: P/014/2021
What was tested
Treatment tested
- Ofatumumab
B-lymphocyte antigen CD20 binding agent
- Siponimod
Sphingosine 1-phosphate receptor Edg-1 agonist
Compared with
What it measured
Main measures
Annualized relapse rate (ARR of confirmed relapses)
Relapses
Other measures (1)
-Annualized relapse rate (ARR of confirmed relapses)
Relapses
Papers
Loading reviews and guidelines…
Related trials
- A Study of C-CAR168 in the Treatment of Autoimmune Diseas…
Phase 1 · Not yet recruiting
Still running
- CN46182
Phase 3 · Running, not recruiting
Still running
- Risk of Progressive Multifocal Leukoencephalopathy Among …
Recruiting
Still running
- Immune System Effects in Children Born to Women With Mult…
Not yet recruiting
Still running
- A Study of C-CAR168 in the Treatment of Central Nervous S…
Phase 1 · Not yet recruiting
Still running
- ML45855
Not a drug-phase study · Not yet recruiting
Still running
History
- In scope changed from true to false
Started
May 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error